Department of Medical Biochemistry, University of Nairobi, Nairobi, Kenya.
Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya.
PLoS One. 2023 Feb 2;18(2):e0281256. doi: 10.1371/journal.pone.0281256. eCollection 2023.
Hepatitis B is becoming a growing public health problem in Kenya. To combat the threat, HBV vaccination should be recommended, particularly for individuals who are not covered by the national immunization program. Vaccination provides sero-protection rates approaching 95% among healthy adults after completing the three-dose vaccination course, but decreases to 87% among those who receive only two doses, emphasizing the importance of completing the three-dose vaccination course. However, data on adult adherence to HBV multi-dose vaccines in Sub-Saharan Africa are limited, despite the fact that this information is critical for prevention. As a result, more research on HBV vaccine dose completion is required. The purpose of this study is to estimate the prevalence of hepatitis B virus infection among out-patient clinic attendees in Nairobi, Kenya, as well as to identify beneficiaries of free vaccination and barriers to completing the recommended vaccine doses.
Between July 30th and September 30th, 2015, 2644 outpatient clinic attendees aged ≥ 4 were recruited from three hospitals in Nairobi County, Kenya: Mama Lucy, Riruta, and Loco. Self-administered questionnaires were used to collect socio-demographic information, and blood samples were tested for hepatitis B surface antigen (HBsAg) using the KEMRI HEPCELL Rapid® (Hepatitis B Detection kit) test kit. Individuals who tested negative for HBsAg were given a free course of three doses of HBV vaccine. The vaccination register provided information on the number of doses administered.
The average age of the study population was 31.4 years (range: 4-66), with females accounting for 59.2%. 1.82% (48/2644) of the participants tested positive for HBsAg. Among the 2596 individuals eligible for vaccination, 66% (1720/2596) received at least one dose, and 51.8% (1345/2596) received all three doses. Vaccination acceptance increased with age, with older patients more likely to return for subsequent dose (OR>1 for second and third dose). Unavailability and failure to contact client were cited as significant (p<0.0001) barrier to vaccination completion by 53.7% (666/1226, 95% CI 0.5-0.6) and 37% (454/1226, 95% CI 0.3-0.4) of respondents respectively.
The prevalence of HBV infection among outpatient clinic attendees highlights the importance of expanding HBV immunization programs in Kenya. However, given the low vaccination completion rate, there is a need for public awareness of the vaccine's importance in preventing HBV and HBV-related complications.
乙型肝炎在肯尼亚正成为日益严重的公共卫生问题。为应对这一威胁,应推荐乙型肝炎病毒(HBV)疫苗接种,特别是针对未纳入国家免疫规划的人群。健康成年人完成三针疫苗接种后,血清保护率接近 95%,但仅接种两针的保护率下降至 87%,这强调了完成三针疫苗接种的重要性。然而,在撒哈拉以南非洲地区,成人对 HBV 多剂量疫苗的接种依从性数据有限,尽管这些信息对于预防至关重要。因此,需要更多关于 HBV 疫苗剂量完成情况的研究。本研究旨在估计肯尼亚内罗毕门诊就诊者中乙型肝炎病毒感染的流行率,并确定免费接种疫苗的受益人群和未完成推荐疫苗剂量的障碍。
2015 年 7 月 30 日至 9 月 30 日,从肯尼亚内罗毕县的三家医院(Mama Lucy、Riruta 和 Loco)招募了年龄≥4 岁的 2644 名门诊就诊者:Mama Lucy、Riruta 和 Loco。采用自我管理问卷收集社会人口统计学信息,使用 KEMRI HEPCELL Rapid®(乙型肝炎检测试剂盒)检测血液样本中的乙型肝炎表面抗原(HBsAg)。HBsAg 检测阴性的个体可免费接种三剂 HBV 疫苗。疫苗接种登记册提供了接种疫苗剂量的信息。
研究人群的平均年龄为 31.4 岁(范围:4-66),女性占 59.2%。2644 名参与者中有 1.82%(48/2644)的 HBsAg 检测呈阳性。在 2596 名符合接种条件的个体中,66%(1720/2596)至少接种了一剂,51.8%(1345/2596)接种了全部三剂。随着年龄的增长,疫苗接种的接受率增加,年龄较大的患者更有可能返回接种后续剂量(第二剂和第三剂的 OR>1)。53.7%(666/1226,95%CI 0.5-0.6)和 37%(454/1226,95%CI 0.3-0.4)的受访者分别提到疫苗接种的可及性和未能联系到患者是疫苗接种完成的重要障碍。
门诊就诊者中 HBV 感染的流行率突出表明,肯尼亚有必要扩大 HBV 免疫规划。然而,鉴于疫苗接种完成率较低,需要提高公众对疫苗在预防 HBV 及相关并发症方面重要性的认识。